{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":20,"n_cols":5,"rows_kept":20,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[13,2,13,3],[14,2,14,3],[17,2,17,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910795443803321"]
[null,null,"Titolo",null,"Office-based buprenorphine treatment of opioid use disorder / / edited by John A. Renner Jr., M.D., Petros Levounis, M.A., Anna T. LaRose, M.D"]
[null,null,"Pubbl/distr/stampa",null,"Arlington, Virginia : , : American Psychiatric Association Publishing, , 2018"]
[{"$nulls":4},"©2018"]
[null,null,"ISBN",null,"1-61537-170-2"]
[null,null,"Edizione",null,"[Second edition.]"]
[null,null,"Descrizione fisica",null,"1 online resource (xix, 375 pages) : illustrations"]
[null,null,"Collana",null,"ProQuest Ebook Central"]
[null,null,"Disciplina",null,"615/.7822"]
[null,null,"Soggetti",null,"Opioid abuse - Chemotherapy"]
[{"$nulls":4},"Buprenorphine - Therapeutic use"]
[{"$nulls":4},"Opioid-Related Disorders - drug therapy"]
[{"$nulls":4},"Buprenorphine - therapeutic use"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Opioid use disorder in america : history and overview / John A. Renner Jr -- General opioid pharmacology / John T. Pichot, Mark T. Pichot -- Efficacy and safety of buprenorphine / Eric C. Strain, Gerard Iru I. Fernando -- Patient assessment / Petros Levounis, Jonathan Avery -- Clinical use of buprenorphine / Ricardo Restrepo, Petros Levounis -- Buprenorphine treatment in office-based settings / Jeffrey D. Baxter, Dong Chan Park -- Psychosocial and supportive treatment / Peter D. Friedmann, Tae Woo Park -- Referral, logistics, and diversion / Joji Suzuki, Claudia P. Rodriguez -- Methadone, naltrexone, and naloxone / Brad W. Stankiewicz, Saria El Haddad, Anna Terajewicz Larose -- Psychiatric comorbidity / Elie Aoun, Elinore F. McCance-Katz -- Medical comorbidity / Joseph H. Donroe, Lynn E. Fiellin, David A. Fiellin, Jeanette M. Tetrault -- Acute and chronic pain / Daniel P. Alford -- Opioid use by adolescents / Ximena Sanchez-Samper, Sharon Levy -- Women's health and pregnancy / Anna T. LaRose, Hendree E. Jones -- Comments on the case vignettes / John A. Renner Jr., Gregory Acampora."]
[null,null,null,"Sommario/riassunto","With a new foreword by Nora Volkow, Director of the National Institute on Drug Abuse, this second edition of Office-Based Buprenorphine Treatment of Opioid Use Disorder provides updated information on evidence-based treatment for opioid use disorder (OUD)—an "]
[{"$nulls":4},"increasingly important topic as the epidemic of opioid misuse and overdose deaths grows in the United States. Bulleted clinical pearls at the end of each chapter, as well as specific clinical recommendations and detailed case discussions throughout, make it easier for readers to retain knowledge and integrate it into their clinical practice. The guide also features sample documentation and scales, including a treatment contract and a patient consent, that can be used to model documents in practice. This new edition of Office-Based Buprenorphine Treatment has been updated to reflect DSM-5 language, and two additional chapters have been included: one that addresses other pharmacotherapies useful in treating OUD, including methadone and naltrexone, and another that discusses OUD treatment specifically with regard to women’s health and pregnancy. A discussion of the Comprehensive Addiction and Recovery Act (CARA). Advice for working with Alcoholics Anonymous and Narcotics Anonymous. A discussion on integrating buprenorphine into residential and inpatient opioid treatment programs. -- Publisher"]